
|Articles|October 28, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Sequencing Agents for the Treatment of Pancreatic NETs
Author(s)Pamela L. Kunz, MD
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).
Advertisement
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).
Learn more about research into the treatment of pancreatic NETs > >
Articles in this issue
about 11 years ago
Unanswered Questions Regarding the Treatment of Pancreatic NETsabout 11 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsabout 11 years ago
Research on Epidemiology of GIST Identifies Risk Factorsabout 11 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationabout 11 years ago
Coping With Comorbidities in Hepatocellular Cancerabout 11 years ago
Strategies in Surveillance: Hepatocellular Carcinomaabout 11 years ago
Immunotherapy and Viral Therapy for Pancreatic CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5






































